OKO.L. Krivusha

O.L. Krivusha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O.L. Krivusha has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medical prevention of respiratory-synchitic viral infection in the present and future

    by O.E. Abaturov, N.M. Tokarieva, O.L. Krivusha

    Respiratory syncytial virus (RSV) is one of the most common respiratory viral agents and the main cause of lower respiratory tract infections in children and the elderly that have an unfavorable outcome. Unfortunately, current national recommendations for the treatment of patients with RSV infection (RSVI) are limited mainly to pathogenetic and symptomatic therapy. Instead, scientists are focusing on the development of new drugs that inhibit the activity of various viral proteins and surface receptor molecules of respiratory tract epithelial cells. Aim - to provide an overview of the main current and future strategies for RSVI prevention. The drug prophylaxis of RSVI, which is recommended in the form of passive and active immunization, is highly effective. Passive immunization is recommended for children, while vaccination is mainly indicated for pregnant women and the elderly. For passive immunization in children, medications containing recombinant monoclonal RSV-neutralizing antibodies, such as palivizumab and nircevimab, are used. Palivizumab is administered intramuscularly once a month throughout the RSV season. At the same time, nirsevimab requires only a single injection to achieve the preventive effect. The duration of the preventive effect of nirsevimab is due to the modification of the mAb molecule, which significantly increases the half-life of the mAb. For children in the first six months of life whose mothers were vaccinated during pregnancy, it is recommended to be vaccinated with Abrisvo vaccine during the period of increased incidence of RSVI. For the prevention of RSVI in the elderly, it is recommended to use Arexvie and Abrisvo vaccines, and for pregnant women - the bivalent subunit Abrisvo vaccine. It is believed that the introduction of new RSVI preventive strategies will significantly reduce both the incidence of the disease and the risk of adverse outcomes from this infection. The authors declare no conflict of interest.

  • Open Access

    Etiological therapy of respiratory-synchitic viral infection in the present and future

    by O.E. Abaturov, N.M. Tokarieva, O.L. Krivusha

    For several decades, acute respiratory infections caused by respiratory syncytial virus (RSV) have been a leading cause of respiratory tract pathology in young children. The aim is to highlight modern concepts of pathogenesis and the main directions of medicamentous treatment of respiratory syncytial virus infection. Two antigenic subtypes of RSV have been identified: A and B, and at least 37 genotypes of RSV type B and 13 genotypes of RSV type A. Respiratory syncytial virus infection (RSVI) in young children is characterized by a high probability of unfavorable life-threatening course, which requires hospitalization. Despite significant advances in virology and molecular biology that reveal the details of RSV interaction with the macrophage and the functioning of RSV replication mechanisms, treatment recommendations for patients with RSVI are limited mainly to pathogenetic and symptomatic therapy. Ribavirin, a nucleoside analog, is the only FDA-licensed antiviral agent for the treatment of RSVI that moderately inhibits viral replication. Instead, scientists are focusing on the development of new drugs that inhibit the activity of various viral proteins and surface receptor molecules of respiratory tract epithelial cells. The most promising drugs in this group are chemical compounds that inhibit RSV protein F, in particular, ziresovir, which is in phase III clinical trials. Currently, the possibility of using receptor tyrosine kinase inhibitors, such as erlotinib and vandetanib, in the treatment of RSVI is being investigated. Non-nucleoside inhibitors of RSV L-protein RNA polymerase, in particular the small molecule PC786, have great prospects for effective use in RSVI. It is also believed that the CX3CR1 receptor is the most promising target for drugs that will be developed to control the level of expression during the prevention and treatment of RSVI. The authors declare no conflict of interest.


  • Open Access

    Development of monoorganic and polyorganic phenotypes of bronchial asthma in children: the role of combined single-nucleotide variants

    by V.O. Dytiatkovskyi, O.L. Krivusha, N.M. Tokareva

    Background. Bronchial asthma (BA) in children is on one of the leading places in the morbidity and mortality structure among other allergic and atopic diseases. It can be developed in the form of a monoorganic phenotype (MOPh) or a polyorganic phenotype (POPh) with other nosologies of atopic march (AM): atopic dermatitis (AD) and allergic rhinitis/rhinoconjunctivitis (AR/ARC). This process is genetically determined, with single-nucleotide variants (SNV) of filaggrin (FLG), thymic stromal lymphopoietin (TSLP) and orsomucoid-like protein 3 ­(ORMDL3) genes playing a major role. The purpose of this study was to reveal the impact of rs_7927894 FLG, rs_11466749 TSLP and rs_7216389 ORMDL3 SNV genotype combinations in the deve­lopment of MOPh and POPh of atopic BA in children. Materials and me­thods. One hundred and twenty-one children of the main group and 105 controls took part in the study. The criteria for inclusion into the main group were: age from 3 to 18 years, clinically established and laboratory confirmed diagnoses of MOPh BA, POPh BA + AR/ARC and AD + AR/ARC + BA. The criteria for inclusion in the control group were: age from 3 to 18 years, exclu­ded diagnoses of BA, BA + AR/ARC and AD + AR/ARC + BA. All children underwent swabbing of the oral mucosa and real-time polymerase chain reaction with the obtained material to detect variants of rs_7927894 FLG, rs_11466749 TSLP and rs_7216389 ORMDL3 genotype combinations. The results were processed ­using the following statistical tools: logistic regression analysis with determination of odds ratio (OR) with 95% confidence interval (95% CI), receiver operating characteristic (ROC) analysis with determination of the area under the ROC curve (AUC), sensitivity (Se), specificity (Sp), Pearson’s correlation coefficient (r), Fisher’s ­exact test, Student’s t-test. The significance value was set at p < 0.05, trend to reliability — at p = 0.0–0.1. Results. The structure of the significantly most frequent genotypes in the cohorts of the main group was as follows: C/T rs_7927894 FLG + C/T rs_7216389 ­ORMDL3 — BA = 8.7 %; C/T rs_7927894 FLG + T/T rs_7216389 ORMDL3: BA = 21.7 %, BA + AR/ARC = 18.1 %, AD + AR/ARC + BA = 15.4 %; C/T rs_7927894 FLG + A/A rs_11466749 TSLP: BA + AR/ARC = 31.9 %, AD + AR/ARC + BA = 42.3 %. Next, indicators of the genotypic combinations impact on the risk of BA phenotypes development related to the control group are provided. MOPh BA: C/T rs_7927894 FLG + T/T rs_7216389 ­ORMDL3: r = 0.299, OR = 9.44 (95% CI 2.07–43.03), AUC = 0.594 (0.507–0.682), Se/Sp = 21.7/97.1 % (p < 0.001). POPh BA + AR/ARC: C/T rs_7927894 FLG + A/A rs_11466749 TSLP: r = 0.136, OR = 1.88 (95% CI 0.94–3.74), AUC = 0.560 (0.493–0.626), Se/Sp 31.9/80.0 % (p = 0.071); C/T rs_7927894 FLG + T/T rs_7216389 ORMDL3: r = 0.260, OR = 7.49 (95% CI 2.05–27.37), AUC = 0.576 (0.528–0.624), Se/Sp = 18.1/97.1 % (p < 0.001). POPh AD + AR/ARC + BA: C/T rs_7927894 FLG + A/A rs_11466749 TSLP: r = 0.207, OR = 2.93 (95% CI 1.18–7.31), AUC 0.612 (0.507–0.716), Se/Sp = 42.3/80.0 % (р < 0.05); C/T rs_7927894 FLG + C/T rs_7216389 ORMDL3: r = 0.173, OR = 2.50 (95% CI 0.99–6.30), AUC = 0.592 (0.489–0.695), Se/Sp = 38.5/80.0 % (p < 0.05); C/T rs_7927894 FLG + T/T rs_7216389 ORMDL3: r = 0.222, OR = 6.18 (95% CI 1.29–29.6), AUC = 0.563 (0.490–0.635), Se/Sp = 15.4/97.1 % (p < 0.01). The ratio of associations and risks for developing the phenotypes rela­ted to each other: BA + AR/ARC related to BA: C/T rs_7927894 FLG + C/T rs_7216389 ORMDL3: r = 0.171, OR = 3.50 (95% CI 0.75–16.41), AUC = 0.582 (0.504–0.659), Se/Sp = 25.0/91.3 % (p = 0.095); AD + AR/ARC + BA related to BA: C/T rs_7927894 FLG + C/T rs_7216389 ­ORMDL3: r = 0.345, OR = 6.56 (95% CI 1.26–34.23), AUC = 0.649 (0.537–0.761), Se/Sp = 38.5/91.3 % (р < 0.05); C/T rs_7927894 FLG + A/A rs_11466749 TSLP: r = 0.270, OR = 3.48 (95% CI 0.92–13.17), AUC = 0.625 (0.500–0.750), Se/Sp 42.3/82.6 % (p = 0.059). Conclusions. MOPh BA has a significant association and an increased risk of development with the SNV genotype combination C/T rs_7927894 FLG + T/T rs_7216389 ORMDL3. POPh BA + AR/ARC has significant associations and increased risks of development with the following SNV genotype combinations: C/T rs_7927894 FLG + A/A rs_11466749 TSLP and C/T rs_7927894 FLG + T/T rs_7216389 ORMDL3. POPh AD + AR/ARC + BA has the most associations and increased risks of development within the following SNV genotype combinations: C/T rs_7927894 FLG + A/A rs_11466749 TSLP, C/T rs_7927894 FLG + C/T rs_7216389 ORMDL3, C/T rs_7927894 FLG + T/T rs_7216389 ORMDL3.

  • Open Access

    The effect of combined therapy with calcium salts and vitamin D on the concentration of macro- and microelements in saliva in young children

    by O.E. Abaturov, T.O. Kryuchko, O.L. Kryvusha, V.L. Babych, N.M. Tokareva, O.Y. Tkachenko

    Background. A balanced supply of macro- and microelements to various organs and systems is a prerequisite for maintaining human health. Deficiency or excess of macro- and microelements in saliva can be associated with both inflammation and oxidative damage to the oral tissues. Provision of calcium in the human body significantly affects the state of salivary ionome. However, currently there are few studies on the effect of Ca and vitamin D on the state of salivary ionome in healthy children. Purpose: to study the effect of combined use of prophylactic doses of Ca and vitamin D on the concentration of macro- and microelements in saliva of young children. Materials and methods. Under our supervision, there were 36 clinically healthy young children who received Calcicare 2.5 ml 3 times a day for 2 months. The study of the content of macro- and microelements in urine was carried out by optical emission spectrometry with an inductively coupled plasma. Statistical analysis of the results was performed using the application package Statistica 6.1 on a personal computer based on Intel Pentium processor. Results. The study showed that the combined use of calcium carbonate and vitamin D significantly changes the concentration of some macro- and microelements in saliva of young children. The level of some trace elements in saliva before the start of therapy with Calcicare correlated with the frequency of acute respiratory infections. Thus, a higher incidence of acute respiratory infections was observed in children with reduced salivary excretion of Ca and S. Young children had a low concentration of Ca and Mg in saliva before the course of Calcicare therapy. Treatment with Calcicare led to an activation of the metabolism of these macronutrients in saliva of young children, which was characterized by an increase in the level of Ca from 29.5 ± 4.4 mg/l to 60.1 ± 6.8 mg/l (p < 0.01), Mg from 4.9 ± 0.6 mg/l to 9.3 ± 0.8 mg/l (p < 0.01), S from 336.3 ± 3.8 mg/l to 2501.6 ± 275.4 mg/l (p < 0.01), and P from 5.6 ± 0.3 mg/l to 15.8 ± 0.7 mg/l (p < 0.01). An increase in the concentration of Ca and P in saliva after the treatment with Calcicare probably has an anti-caries effect. An increase in the level of Mg in saliva after the course of Calcicare may have anti-inflammatory and antitumor effect on the oral mucosa. Co-administration of calcium carbonate and vitamin D led to the disappearance of salivary excretion of some trace elements such as B, Cd, Li, Pb, which may relieve the oral mucosa and dental tissues from the toxic effects of these trace elements. Conclusions. The combined use of calcium carbonate and vitamin D (Calcicare) for 2 months in young children is accompanied by changes in salivary ionome, which are of anti-inflammatory and anti-caries nature. After taking calcium carbonate and vitamin D, there was a cessation of salivary excretion of some trace elements, which have a toxic effect on the oral tissues. The use of Calcicare in the recommended dose of 2.5 ml 3 times a day for 2 months is characterized by a high safety profile and can be recommended for young children, especially those at risk of developing calcium deficiency.